Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)

Evaluation of Clinical Responsiveness Using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02945345

Acronym

CDASI

Enrollment

300

Registered

2016-10-26

Start date

2008-06-01

Completion date

2030-01-02

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatomyositis

Brief summary

The Evaluation of Clinical Responsiveness Using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), established in 2008, is a one-site database study conducted at the University of Pennsylvania. The database has yielded valuable information and clinical insights into the pathophysiology, disease processes, including psychological responses, treatments and quality of life associated with dermatomyositis. The CDASI database incorporates the Cutaneous Dermatomyositis Disease Area and Severity Index), a validated outcome measure of disease responsiveness in patients, and other assessment tools, surveys and patient information to help validate the clinical course and quality of life of patients with dermatomyositis. The CDASI database has led to publication of comparison studies of CDASI and other clinical instruments and the effect of dermatomyositis on Quality of Life (QoL). The CDASI database is an ongoing resource that enables clinicians to evaluate the evolving clinical changes, treatment modalities and patient response to a challenging disease. Data will be analysed over a 5 years.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Gender/Age: Males or females above 18 years old * Diagnosis: Cutaneous Dermatomyositis * Subjects able to give informed consent

Exclusion criteria

* Subjects without cutaneous DM * Penn employees * Penn students * Cognitively impaired persons

Design outcomes

Primary

Measure	Time frame	Description
Cutaneous Dermatomyositis Disease Area and Severity Index	through study completion, an average of 1 year	Disease severity tool

Secondary

Measure	Time frame	Description
Skin quality of life tool	through study completion, an average of 1 year	Quality of life tool

Countries

United States

Contacts

CONTACTVictoria Werth, MD

werth@pennmedicine.upenn.edu215-615-2940

CONTACTJoyce Okawa, RN

joyce.okawa@pennmedicine.upenn.edu215-615-2940

Outcome results